Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,007 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 31,007 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 750 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse/Cust Son | 400 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 400 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 1,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001225471-26-000002 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001225471-26-000002 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,007 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 22:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,212 | $0.00 Strike: $520.01 | $0.00 |
DisclosureSEC source: 0001225471-25-000006 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,212 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 22:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,188 | $774.03 | $4,789,697.64 |
DisclosureSEC source: 0001225471-25-000006 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,852 Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 22:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 9,212 | $520.01 | $4,790,332.12 |
DisclosureSEC source: 0001225471-25-000006 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000001 · edgardoc.xml · derivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000001 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,828 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,338 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001968202-25-000001 · edgardoc.xml · derivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,338 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,948 | $708.19 | $1,379,554.12 |
DisclosureSEC source: 0001968202-25-000001 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,662 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,338 | $413.33 | $1,379,695.54 |
DisclosureSEC source: 0001968202-25-000001 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000126 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,272 Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:20 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001883850-24-000020 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,338 Underlying: Common Stock · 2,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:20 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 877 | $942.53 | $826,598.81 |
DisclosureSEC source: 0001883850-24-000020 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,472 Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:20 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $413.33 | $826,660.00 |
DisclosureSEC source: 0001883850-24-000020 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001968202-24-000079 · edgardoc.xml · derivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,338 Underlying: Common Stock · 1,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $995.00 | $497,500.00 |
DisclosureSEC source: 0001968202-24-000079 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $413.33 | $206,665.00 |
DisclosureSEC source: 0001968202-24-000079 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $990.00 | $495,000.00 |
DisclosureSEC source: 0001968202-24-000079 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $413.33 | $206,665.00 |
DisclosureSEC source: 0001968202-24-000079 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · derivative · entry 13 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,338 Underlying: Common Stock · 500 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $985.00 | $492,500.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $413.33 | $206,665.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · derivative · entry 12 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,838 Underlying: Common Stock · 3,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $960.00 | $960,000.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $413.33 | $413,330.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $965.00 | $965,000.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $413.33 | $413,330.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $970.00 | $970,000.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $413.33 | $413,330.00 |
DisclosureSEC source: 0001968202-24-000072 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001968202-24-000062 · edgardoc.xml · derivative · entry 9 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,838 Underlying: Common Stock · 500 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $955.00 | $477,500.00 |
DisclosureSEC source: 0001968202-24-000062 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $413.33 | $206,665.00 |
DisclosureSEC source: 0001968202-24-000062 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001968202-24-000062 · edgardoc.xml · derivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,338 Underlying: Common Stock · 500 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $945.00 | $472,500.00 |
DisclosureSEC source: 0001968202-24-000062 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $413.33 | $206,665.00 |
DisclosureSEC source: 0001968202-24-000062 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000024 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000024 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,349 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000016 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000016 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,214 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $617.00 | $617,000.00 |
DisclosureSEC source: 0001883850-22-000014 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,049 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $614.00 | $614,000.00 |
DisclosureSEC source: 0001883850-22-000014 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,049 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $621.00 | $1,242,000.00 |
DisclosureSEC source: 0001883850-22-000014 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,049 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001708138-22-000007 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-22-000007 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,049 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $660.00 | $660,000.00 |
DisclosureSEC source: 0001883850-21-000012 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,858 Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $655.00 | $655,000.00 |
DisclosureSEC source: 0001883850-21-000012 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,858 Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $655.00 | $655,000.00 |
DisclosureSEC source: 0001883850-21-000012 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,858 Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,000 | $650.00 | $2,600,000.00 |
DisclosureSEC source: 0001237899-21-000024 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,858 Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 750 | $650.00 | $487,500.00 |
DisclosureSEC source: 0001237899-21-000024 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 1,000 Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $660.00 | $1,320,000.00 |
DisclosureSEC source: 0001237899-21-000024 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,858 F1 · price: Represents volume-weighted average price of sales of 2,000 shares of Company stock on November 16, 2021 at prices ranging from $660.00 to $660.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.